Guggenheim raises Travere Therapeutics stock price target on FSGS approval

TVTX is transitioning from a binary regulatory story into a duration story: the market is now pricing a multi-year exclusivity window and a much larger treatable population, which matters more than the latest target revision. The key second-order effect is that launch quality and persistence will drive valuation more than headline approval, because in rare disease franchises the discount rate collapses only after reimbursement, specialist adoption, and repeat dosing data all de-risk execution.

The broader label is the real option value. It expands the addressable pool and, more importantly, makes the franchise less dependent on any single subtype, which should improve payer negotiability and reduce the probability of a one-trial narrative break. That said, consensus is probably underestimating how quickly competitors, payers, and treatment guidelines will respond if utilization ramps faster than expected; when a rare-disease drug starts looking like a billion-dollar product, the scrutiny shifts from science to access and durability.

Near term, the stock is likely to trade on launch metrics over the next 1-3 quarters: prescription momentum, REMS/payer friction, and whether the pediatric expansion adds incremental demand or just shifts timing. The main tail risk is that label breadth does not translate into broad clinical adoption if nephrology specialists remain conservative on who is truly eligible; in that case the equity could de-rate even with good approval headlines. Longer term, the most important upside catalyst is exclusivity extension, because each incremental year should disproportionately expand DCF if peak sales are real and the asset becomes the anchor of the franchise.